Eris Lifesciences Limited
NSE:ERIS.NS
1465.5 (INR) • At close May 8, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) INR.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 19,912.95 | 16,618.16 | 13,261.68 | 11,926.44 | 10,581.83 | 9,672.02 | 8,556.04 | 7,249.57 | 5,970.21 | 5,455.58 | 5,088.22 | 3,930.64 |
| Cost of Revenue
| 9,966.77 | 3,523.5 | 2,608.06 | 2,418.69 | 1,787.36 | 1,551.44 | 1,362.22 | 1,068.03 | 1,005.94 | 961.74 | 1,003.64 | 750.33 |
| Gross Profit
| 9,946.18 | 13,094.66 | 10,653.62 | 9,507.75 | 8,794.47 | 8,120.58 | 7,193.82 | 6,181.54 | 4,964.27 | 4,493.84 | 4,084.58 | 3,180.31 |
| Gross Profit Ratio
| 0.499 | 0.788 | 0.803 | 0.797 | 0.831 | 0.84 | 0.841 | 0.853 | 0.832 | 0.824 | 0.803 | 0.809 |
| Reseach & Development Expenses
| 57.18 | 61 | 327.38 | 50.92 | 41.96 | 41.12 | 7.74 | 0 | 0 | 0 | 0 | 0 |
| General & Administrative Expenses
| 714.79 | 471.75 | 504.09 | 430.35 | 352.91 | 317.71 | 335.05 | 362.83 | 332.1 | 362.33 | 318.47 | 309.23 |
| Selling & Marketing Expenses
| 1,789.3 | 1,390.02 | 1,016.53 | 1,080.81 | 1,463.29 | 1,185.23 | 924.96 | 696.35 | 709.94 | 604.41 | 1,024.52 | 547.43 |
| SG&A
| 4,787.54 | 1,861.77 | 1,520.62 | 1,511.16 | 1,816.2 | 1,502.94 | 1,260.01 | 1,059.18 | 1,042.04 | 966.74 | 1,342.99 | 856.66 |
| Other Expenses
| 0 | 111.53 | 10.36 | 4.55 | 36.62 | 17.4 | 7.42 | 0.86 | 0.17 | 0.78 | 1,798.86 | 0.04 |
| Operating Expenses
| 4,942.94 | 8,898.08 | 6,403 | 5,620.02 | 5,559.57 | 5,011.06 | 4,229 | 3,725.99 | 3,422.81 | 3,434.11 | 3,141.85 | 2,314.16 |
| Operating Income
| 4,953 | 4,216.63 | 4,245.04 | 3,876.09 | 3,218.52 | 3,088.81 | 2,964.82 | 2,455.55 | 1,541.46 | 1,059.73 | 942.73 | 866.15 |
| Operating Income Ratio
| 0.249 | 0.254 | 0.32 | 0.325 | 0.304 | 0.319 | 0.347 | 0.339 | 0.258 | 0.194 | 0.185 | 0.22 |
| Total Other Income Expenses Net
| -640.61 | -248.41 | -3,250.27 | -16.73 | 78.6 | 64.06 | 157.47 | 238.24 | 2.98 | 34.42 | 40.52 | -34.76 |
| Income Before Tax
| 4,312.39 | 4,046.43 | 4,421.98 | 3,944.97 | 3,313.5 | 3,173.58 | 3,122.29 | 2,637.72 | 1,544.44 | 1,094.15 | 983.25 | 831.39 |
| Income Before Tax Ratio
| 0.217 | 0.243 | 0.333 | 0.331 | 0.313 | 0.328 | 0.365 | 0.364 | 0.259 | 0.201 | 0.193 | 0.212 |
| Income Tax Expense
| 341.85 | 304.83 | 364.09 | 393.62 | 348.43 | 262.11 | 172.51 | 218.72 | 195.87 | 201.56 | 277.88 | 246.99 |
| Net Income
| 3,919.83 | 3,821.58 | 4,061.13 | 3,551.35 | 2,964.97 | 2,907.96 | 2,941.05 | 2,420.79 | 1,335.69 | 892.34 | 704.19 | 581.98 |
| Net Income Ratio
| 0.197 | 0.23 | 0.306 | 0.298 | 0.28 | 0.301 | 0.344 | 0.334 | 0.224 | 0.164 | 0.138 | 0.148 |
| EPS
| 28.82 | 28.1 | 29.89 | 26.16 | 21.61 | 21.15 | 21.39 | 17.95 | 9.71 | 6.49 | 5.12 | 4.23 |
| EPS Diluted
| 28.79 | 28.07 | 29.88 | 26.14 | 21.59 | 21.13 | 21.39 | 17.95 | 9.71 | 6.49 | 5.12 | 4.23 |
| EBITDA
| 6,986.45 | 5,480.76 | 5,111.22 | 4,394.57 | 3,839.05 | 3,767.72 | 3,479.58 | 2,934.01 | 1,677.7 | 1,249.47 | 1,033.39 | 873.36 |
| EBITDA Ratio
| 0.351 | 0.33 | 0.385 | 0.368 | 0.363 | 0.39 | 0.407 | 0.405 | 0.281 | 0.229 | 0.203 | 0.222 |